- Thursday 11th December
- 13:00 – 15:00 (BRT)
- This webinar will be delivered entirely in Portuguese.
Are you looking to strengthen your understanding of the ICH M7(R2) guideline and learn practical approaches to conducting compliant impurity risk assessments?
Join our experts for this live webinar, delivered fully in Portuguese, as we explore how the ICH M7 framework supports the assessment and control of DNA-reactive (mutagenic) impurities in pharmaceuticals, helping to limit potential carcinogenic risk.
Our speakers will discuss how to apply ICH M7 principles in practice using Lhasa Limited expert knowledge-based and statistical in silico tools, Derek Nexus and Sarah Nexus, to support scientifically robust and defensible impurity assessments.
You’ll also hear an exclusive case study from Libbs Farmacêutica, a leading Brazilian pharmaceutical company, demonstrating how ICH M7 principles are being implemented in real-world scenarios.
Meet the speakers
- Roberta Drekener, Senior Application Scientist, Lhasa Limited
- Karen Rafaela Gonçalves de Araújo, Development Analyst, Libbs Farmacêutica
- Plus a Scientific Consultant, Spektra Consultoria
Why attend?
- Gain a clear understanding of ICH M7(R2) and its impact on pharmaceutical impurity management.
- See how in silico tools can enhance the efficiency and scientific defensibility of your risk assessments.
- Learn from Brazilian experts already applying ICH M7 principles in practice.
Register to attend using the form below: